OBR Daily Commentary

forumImage

Roche Cancer Drug Taking Bite Out Of Bristol's Opdivo

(Reuters) Jan 27, 2017 - Roche's cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker's treatment is making up lost ground.

Read Article arrow

H. Jack West, MD (Posted: January 27, 2017)

quotesIt's not surprising that the second line NSCLC market has shifted away from nivolumab to atezolizumab and pembrolizumab from nivolumab enjoying the overwhelming majority of that market share a year ago. The recent presentation of newer data and subsequent FDA approvals have meant that atezolizumab is now a second line option given on a more convenient every 3 week schedule vs. nivolumab's every 2 week schedule, while both have no requirement for any PD-L1 testing or a threshold level of expression. Even though pembrolizumab requires at least 1% staining for second line use based on the revision of that indication, the new approval of pembrolizumab as first line therapy for high PD-L1 expressors means that the vast majority of NSCLC are now being routinely tested for PD-L1 expression in their initial workup as a standard of care, whereas PD-L1 testing was not previously a necessary step. This means that pembrolizumab, as another every 3 week option, compares favorably as an alternative to atezolizumab for any patients with > or =1% PD-L1 expression. Finally, though the negative results from Checkmate-026, comparing nivolumab to standard chemotherapy in first line NSCLC, do not speak to the second line setting, it is likely that this has led to somewhat lower enthusiasm toward nivolumab when comparable checkpoint inhibitor options have a more attractive treatment schedule and have not been tainted by negative first line results, at least not yet.quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Professor and Chair, Department of Radiation Oncology...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Health Policy
member photo
Joseph Bailes, MD

National Health Policy Expert...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Professor and Physician-in-Chief of the Ohios State Uni...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...